HK1059391A1 - Use of quetiapine for the treatment of cocaine dependence - Google Patents

Use of quetiapine for the treatment of cocaine dependence

Info

Publication number
HK1059391A1
HK1059391A1 HK04102282A HK04102282A HK1059391A1 HK 1059391 A1 HK1059391 A1 HK 1059391A1 HK 04102282 A HK04102282 A HK 04102282A HK 04102282 A HK04102282 A HK 04102282A HK 1059391 A1 HK1059391 A1 HK 1059391A1
Authority
HK
Hong Kong
Prior art keywords
quetiapine
treatment
cocaine dependence
substance
dependence
Prior art date
Application number
HK04102282A
Other languages
English (en)
Inventor
S Brown
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HK1059391A1 publication Critical patent/HK1059391A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Addiction (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
HK04102282A 2001-02-06 2004-03-29 Use of quetiapine for the treatment of cocaine dependence HK1059391A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26680801P 2001-02-06 2001-02-06
PCT/SE2002/000214 WO2002062346A1 (en) 2001-02-06 2002-02-05 Method of treating substance abuse with quetiapine

Publications (1)

Publication Number Publication Date
HK1059391A1 true HK1059391A1 (en) 2004-07-02

Family

ID=23016078

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04102282A HK1059391A1 (en) 2001-02-06 2004-03-29 Use of quetiapine for the treatment of cocaine dependence

Country Status (8)

Country Link
US (2) US7304047B2 (xx)
EP (1) EP1359919B1 (xx)
JP (1) JP2004518699A (xx)
AT (1) ATE360425T1 (xx)
DE (1) DE60219761T2 (xx)
ES (1) ES2284830T3 (xx)
HK (1) HK1059391A1 (xx)
WO (1) WO2002062346A1 (xx)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050171088A1 (en) * 2004-01-30 2005-08-04 Astrazeneca Ab Treatment of psychoses with dibenzothiazepine antipsychotic
EP1838325A1 (en) * 2005-01-07 2007-10-03 AstraZeneca AB NEW USE OF 11-PIPERAZIN-1-YLDIBENZO [b,f][1,4]THIAZEPINE OR ITS PHARMACEUTICALLY ACCEPTABLE SALT AND TO ORAL PHARMACEUTICAL COMPOSITIONS
WO2007067714A2 (en) * 2005-12-08 2007-06-14 The Mclean Hospital Corporation Treatment of sequelae of psychiatric disorders
CA2704279C (en) * 2006-11-03 2014-09-30 University Of Saskatchewan Method of treating demyelination diseases
US9993486B1 (en) 2017-06-19 2018-06-12 Tlc Therapeutics, Llc Oral quetiapine suspension formulations with extended shelf life and enhanced bioavailability
US11545173B2 (en) * 2018-08-31 2023-01-03 The Regents Of The University Of Michigan Automatic speech-based longitudinal emotion and mood recognition for mental health treatment

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607684D0 (en) 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
TW587938B (en) * 1997-03-27 2004-05-21 Akzo Nobel Nv Pharmaceutical composition for the treatment and/or prophylaxis of psychotic disorder
WO2000071106A2 (en) 1999-05-19 2000-11-30 Astrazeneca Ab Method of treating weight gain

Also Published As

Publication number Publication date
US20040058910A1 (en) 2004-03-25
US20070249582A1 (en) 2007-10-25
EP1359919A1 (en) 2003-11-12
EP1359919B1 (en) 2007-04-25
US7304047B2 (en) 2007-12-04
DE60219761D1 (de) 2007-06-06
ES2284830T3 (es) 2007-11-16
JP2004518699A (ja) 2004-06-24
WO2002062346A1 (en) 2002-08-15
ATE360425T1 (de) 2007-05-15
DE60219761T2 (de) 2008-01-17

Similar Documents

Publication Publication Date Title
EP1416961A4 (en) COMPOSITION AND METHOD FOR THE TREATMENT OF A DISEASE
HK1048949A1 (en) Method and composition for the treatment of scars
GB0110288D0 (en) Composition and treatment method
AU8485701A (en) Surgical instrumentation and method for treatment of the spine
IL159422A0 (en) Methods and compositions for treating or preventing skin disorders using binding agents specific for prostate-specific membrane antigen
HK1089364A1 (en) Topical compositions and methods for treating pain
EP1405933A4 (en) TREATMENT SOLUTION FOR SURFACE TREATMENT OF METAL AND SURFACE TREATMENT METHOD
AU2002351378A8 (en) Method and apparatus for treatment of amblyopia
IL162153A0 (en) Methods and compositions for treatment of central nervous systemdisorders
EP1356278A4 (en) METHODS AND COMPOSITIONS FOR IDENTIFYING AND TREATING NEURODEGENERATIVE DISORDERS
EP1409015A4 (en) METHODS OF TREATING OR PREVENTING SKIN DISORDERS USING CD2 BINDING AGENTS
AU2002367023A8 (en) Compositions and methods for treating heart failure
MXPA02012907A (es) Procedimiento para encontrar compuestos que son adecuados para el tratamiento y/o la profilaxia de la obesidad.
EP1379236A4 (en) TREATMENT OF TICS, TREMORS AND RELATED DISORDERS
AU2002365057A8 (en) Compositions and methods for treating heart failure
HK1069829A1 (en) Surface treatment composition and method
PL368948A1 (en) Process and composition for treating wood
AU2002362115A8 (en) Composition and methods for treatment of neurological disorders
HK1059391A1 (en) Use of quetiapine for the treatment of cocaine dependence
IL144718A0 (en) Method and apparatus for the treatment of domestic waste
GB2399500B (en) Composition and method for treatment of wounds
AU2001273759A1 (en) Essential oils and chemically related species for the treatment of increased bone resorption
SG102679A1 (en) Surface treatment method and material treated by the method
AU2003275433A8 (en) Compositions and methods for treating pain
EP1795199A3 (en) Quetiapine for the treatment of substance dependence or substance abuse

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20110205